Skip to content

Study · Animal study (in vivo) · rat · 1997

4 results

The major metabolite of dipeptide piracetam analogue GVS-111 in rat brain and its similarity to endogenous neuropeptide cyclo-L-prolylglycine.

Gudasheva TA, Boyko SS, Ostrovskaya RU, Voronina TA, Akparov VK, Trofimov SS, Rozantsev GG, Skoldinov AP, Zherdev VP, Seredenin SB

European journal of drug metabolism and pharmacokinetics1 Jul 1997Cited by 13 (Europe PMC)

PMID9358206 (opens in a new tab)DOI10.1007/bf03189814 (opens in a new tab)PepBankPUB-09358206
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

2 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Pharmacokinetics

    In rats, brain GVS-111 was below the HPLC detection limit 1 h after administration.

    In plain wordsIn rats, GVS-111 was undetectable in the brain one hour after administration.

    Peptide
    Noopept (omberacetam)
    Outcome
    Not applicableBrain parent compound detection
    Study

    ratn: not reported in source

    Rat brain metabolism
    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    5 mg/kg · intraperitoneal · 1 hAs given in this study (rat).

    Source sentences

    Summary
    GVS-111 itself was not found in rat brain 1 h after 5 mg/kg i.p. administration up to limit of detection (LOD) under high performance liquid chromatography (HPLC) conditions.
  2. 02AnimalAnimal study (in vivo)Pharmacokinetics

    In rats, brain cyclo-prolylglycine concentration increased 2.5-fold 1 h after GVS-111 administration.

    In plain wordsIn rats, brain cyclo-prolylglycine increased after GVS-111 administration.

    Peptide
    Noopept (omberacetam)
    Outcome
    IncreaseBrain cyclo-prolylglycine concentration
    Study

    ratn: not reported in source

    Rat brain metabolism
    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    5 mg/kg · intraperitoneal · 1 hAs given in this study (rat).

    Measurements

    Cyclo-prolylglycine concentration increase
    2.5 fold
    1 h after GVS-111 administration

    Source sentences

    Summary
    Only cyclo-prolylglycine concentration increased (2.5-fold) 1 h after GVS-111 administration.

Studies that did not test the peptide alone2

In this study, Noopept (omberacetam) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Noopept (omberacetam).

  1. 03AnimalNot a test of Noopept (omberacetam) aloneAnimal study (in vivo)Pharmacokinetics

    In rats, phenylacetic acid, prolylglycine and cyclo-prolylglycine were detected in experimental and control brain samples.

    In plain wordsIn rats, three possible GVS-111 metabolites were present in both experimental and control brains.

    Peptide
    Noopept (omberacetam)
    Outcome
    Not applicableBrain metabolite detection
    Study

    ratn: not reported in source

    Rat brain metabolism
    Outcome group
    Pharmacokinetics · Pharmacology

    Source sentences

    Summary
    Three substances corresponding to the three possible GVS-111 metabolites, namely phenylacetic acid, prolylglycine and cyclo-prolylglycine, were found in experimental rat brain samples as well as in controls using HPLC, gas chromatography (GC) and gas chromatography-mass spectrometry (GC-MS) methods.

    In this study, Noopept (omberacetam) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Noopept (omberacetam).

  2. 04LabNot a test of Noopept (omberacetam) aloneIn vitro (cell-free)Pharmacokinetics

    In vitro, plasma and brain enzymes converted GVS-111 to cyclo-prolylglycine.

    In plain wordsIn lab tests, plasma and brain enzymes converted GVS-111 to cyclo-prolylglycine.

    Peptide
    Noopept (omberacetam)
    Outcome
    Not applicableEnzymatic cyclo-prolylglycine formation
    Study

    ratn: not reported in source

    Plasma and brain enzymes
    Outcome group
    Pharmacokinetics · Pharmacology

    Source sentences

    Summary
    Cyclo-prolylglycine formation from GVS-111 in the presence of plasma and brain enzymes was shown in vitro.

    In this study, Noopept (omberacetam) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Noopept (omberacetam).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    21 Oct 2026, 15:58 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 12:50 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.